{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:12:12Z","timestamp":1761045132029,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.urolonc.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T03:05:38Z","timestamp":1703041538000},"page":"70.e11-70.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-2457","authenticated-orcid":false,"given":"Satoshi","family":"Katayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasushi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kawago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Moriwake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Kuinose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sakaeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Shirasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Morinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Sekito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sadahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Edamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Kusumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morito","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadasu","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ebara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.urolonc.2023.11.009_bib0001","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.urolonc.2023.11.009_bib0002","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3390\/cancers13215517","article-title":"Prognostic and predictive factors in advanced urothelial carcinoma treated with immune checkpoint inhibitors: a review of the current evidence","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.urolonc.2023.11.009_bib0003","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4-5","key":"10.1016\/j.urolonc.2023.11.009_bib0004","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2023.11.009_bib0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.009_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10147-021-02061-0","article-title":"Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis","volume":"27","author":"Yanagisawa","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2023.11.009_bib0007","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.21037\/atm.2019.01.74","article-title":"The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab","volume":"7","author":"Friedlander","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.urolonc.2023.11.009_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.009_bib0009","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2023.11.009_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-34461-0_18","article-title":"Hypoxia compromises anti-cancer immune responses","volume":"1232","author":"Multhoff","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.urolonc.2023.11.009_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.009_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/imm.12380","article-title":"Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment","volume":"143","author":"Kumar","year":"2014","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.urolonc.2023.11.009_bib0013","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.urolonc.2023.11.009_bib0014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2023.11.009_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.773168","article-title":"What happens to the immune microenvironment after PD-1 inhibitor therapy?","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.urolonc.2023.11.009_bib0016","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/1078-0432.CCR-18-1311","article-title":"Bigger is not always better: tumor size and prognosis in advanced melanoma","volume":"24","author":"Warner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.009_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000500885","article-title":"Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice","volume":"97","author":"Faehling","year":"2019","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.009_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000258","article-title":"Clinical correlates of response to anti-PD-1-based therapy in patients with metastatic melanoma","volume":"42","author":"Davis","year":"2019","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.009_bib0019","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2019-0814","article-title":"Lack of association between radiographic tumor burden and efficacy of immune checkpoint inhibitors in advanced lung cancer","volume":"25","author":"Popat","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.009_bib0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2023.11.009_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.009_bib0022","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2022.11.032","article-title":"Rationale for LDH-targeted cancer immunotherapy","volume":"181","author":"Miholjcic","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.009_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CMR.0000000000000520","article-title":"Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis","volume":"29","author":"Petrelli","year":"2019","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.009_bib0024","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cam4.2024","article-title":"Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:04Z","timestamp":1761042484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923003617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1078143923003617"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}